# Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

> **NCT00022698** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 67 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00022698
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2004-12
- **Final completion:** 2004-12
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00022698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00022698, "Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00022698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*